GlassScriptPhysician profile
Antoni A Allen
NPI 1548499049
$564.03
in general payments reported to CMS, 2019-2025
15 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $42.82 · 2021: $18.63 · 2022: $36.98 · 2023: $65.06 · 2024: $143 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.38 | 2019-2021 | |
| Horizon Therapeutics Plc | $58.83 | 2022-2023 | Tepezza |
| Dompe US, INC. | $56.04 | 2025 | Oxervate |
| Astellas Pharma US INC | $48.65 | 2024 | Izervay |
| Amgen INC. | $46.64 | 2024 | Tepezza |
| Alcon Vision LLC | $44.73 | 2020-2025 | Clareon |
| Bausch & Lomb Americas INC. | $36.80 | 2024-2025 | Miebo, Xiidra, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $34.03 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.79 | 2019 | |
| Apellis Pharmaceuticals, INC. | $27.06 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $24.55 | 2019 | |
| Oyster Point Pharma, INC. | $22.29 | 2023 | Tyrvaya |
| Abbvie INC. | $20.92 | 2023 | Alphagan P, Vuity, Lumigan |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $18.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoni Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.